Pazopanib HCL intermediates manufacturer

Pazopanib HCL intermediates
Tel: +86-311-67591193 sales@dingminpharma.com
News
Your location: Home » News

Selexipag manufacturers

Selexipag (brand name Uptravi) is a drug developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.
A member of the class of pyrazines that is N-(methanesulfonyl)-2-{4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetamide carrying two additional phenyl substituents at positions 5 and 6 on the pyrazine ring. An orphan drug used for the tre tment of pulmonary arterial hypertension. It is a prodrug for ACT-333679 (the free carboxylic acid).
Our business philosophy is to provide high quality products, great service and competitive price for customers. Your satisfaction is our perseverant pursuit. Welcome to our company when you are convenient.
Other Article
PRODUCTS LIST
CONTACT US
Office Address: No.41, Zhaiying South Street, Yuhua District, Shijiazhuang, Hebei Province.China
R&D and Plant Address: JingShi Cooperative Innovation Industrial Park,No.769 Taihang Street,High-tech Zone,Shijiazhuang
Tel: +86-311-67591193
Fax: +86-311-67591193
sales@dingminpharma.com
Online Service×